Back to Journals » International Journal of Women's Health » Volume 4

Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the midtrimester of pregnancy

Authors Khandelwal M

Received 9 July 2012

Accepted for publication 14 August 2012

Published 14 September 2012 Volume 2012:4 Pages 481—490

DOI https://doi.org/10.2147/IJWH.S28944

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Video abstract presented by Meena Khandelwal

Views: 8902

Meena Khandelwal

Department of Obstetrics and Gynecology, Cooper University Hospital, Camden, NJ, USA

Abstract: Preterm birth is a major health problem for the neonate, family, country, and society in general. Despite many risk factors being identified for women destined to deliver preterm, short cervical length detected on transvaginal ultrasound is the most plausible, practical and sensitive risk factor for prediction of spontaneous preterm birth. The definition of short cervix has varied in various studies, but most commonly accepted is #2.5 cm in the midtrimester of pregnancy, though risk of spontaneous preterm birth (sPTB) increases as the cervical length decreases. Vaginal progesterone, a naturally occurring steroid hormone, is the most bioavailable form of progesterone for uterine and cervical effects with the fewest side effects. Multiple prospective studies have consistently shown its benefits in decreasing sPTB rate in women with asymptomatic midtrimester short cervix. The safety for mother and fetus, and tolerability of vaginal progesterone, particularly the gel form, is also well established. Vaginal progesterone is a minimally invasive intervention that is not painful and is very safe, with reasonable cost where the benefits (even if argued to be small) clearly outweigh the risks. Thus there should be little hesitation for implementation of universal transvaginal cervical length screening and preventive vaginal progesterone treatment for women with short cervix.

Keywords: preterm birth, progesterone, short cervix

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]